Novartis has agreed to pay BoomRay up to $900 million for exclusive global rights to an undisclosed preclinical radioligand therapy asset.
|Articles|January 11, 2022
- Pharmaceutical Executive-01-01-2022
- Volume 42
- Issue 1
Our View on 2022: Pharm Exec’s Annual Industry Outlook
Advertisement
Follow the links below to read about each trend:
Articles in this issue
over 4 years ago
Keeping Tabs on Quality: The Rise of Digitalover 4 years ago
China Invests in Building Biotechover 4 years ago
Branding Takes on a New Lookover 4 years ago
Addressing Access Burdensover 4 years ago
Meeting the Patient—Virtuallyover 4 years ago
The Age of Influenceover 4 years ago
Boosting Immunotherapiesover 4 years ago
Pharma’s Psychedelic Experienceover 4 years ago
Supply Chain Procurementover 4 years ago
Breaking New Ground in BiopharmaAdvertisement
Related to this article
Five major pharma stories in one day — Novo's rebrand and AI bets, Bayer's 30-year CKD first, GSK's T-cell engager, and Sanofi's portfolio exit.
Advertisement
Advertisement
Trending on PharmExec
1
InnoCare Enters $3.35 Billion Research Collaboration and License Agreement with Eli Lilly
2
From Experimentation to Execution: Strategic AI Adoption and Clinical Data Harmonization in Life Sciences
3
The Legacy of Rutledge: How States and Congress Can Still Regulate Pharmacy Benefit Managers
4
FDA Approves Onswik for Adults with Type 2 Diabetes
5